Unravelling the Enzymatic Mechanisms Underlying Phthalate Exposure: Implications for Human and Animal Health Risk Assessment

Sanjib Kumar Mohanty[1], Yashaswi Nayak[1*]

Department of Zoology, Centurion University of Technology and Management, Bhubaneswar

*Author for correspondence: mohantysanjib698@gmail.com, yashaswi.nayak@cutm.ac.in,

Abstract:-

Phthalates, ubiquitous in the environment due to their extensive use in consumer products, pose significant health risks to both humans and animals. Exposure to phthalates occurs through various routes, including ingestion, inhalation, and dermal contact. Once absorbed, phthalates undergo biotransformation in the body, primarily through hydrolysis and oxidation pathways, leading to the formation of metabolites with varying toxicological properties. Metabolism plays a crucial role in modulating the bioavailability and toxicity of phthalates, influencing their distribution, accumulation, and elimination kinetics within biological systems. Phthalates exert their adverse effects through multiple mechanisms, including endocrine disruption, oxidative stress, inflammation, and epigenetic modifications. As endocrine-disrupting chemicals (EDCs), phthalates interfere with hormone signaling pathways, disrupting normal physiological processes such as reproductive function, development, and metabolism. Furthermore, phthalate-induced oxidative stress and inflammation contribute to tissue damage and promote the onset and progression of various diseases. Risk assessment of phthalate exposure involves evaluating the potential hazards associated with specific phthalate compounds, considering factors such as potency, exposure levels, and susceptibility of the exposed population. Epidemiological studies have provided valuable insights into the health effects of phthalates in humans, while experimental animal models have elucidated underlying mechanisms and dose-response relationships. The objectives of my study are to comprehensively review the current literature on phthalates, focusing on their sources, exposure pathways, health effects, and regulatory measures. By synthesizing existing research findings, the review aims to provide a thorough understanding of the potential risks posed by phthalates to human health and the environment.

Introduction

Phthalates, a group of chemicals primarily utilized as plasticizers to enhance the flexibility and durability of plastics, have garnered significant attention due to their widespread use and potential health risks. Commonly found in PVC products, cosmetics, personal care items, and household goods,

phthalates have been associated with concerns regarding endocrine disruption and adverse reproductive and developmental effects(**Hauser et al., 2006**). Regulatory bodies worldwide have implemented restrictions on certain phthalates in consumer products, particularly those intended for children, reflecting growing awareness of their potential hazards. Efforts to address these concerns include the exploration of alternative plasticizers and ongoing research into the health and environmental impacts of phthalates. Despite their utility, the environmental persistence and potential health effects of phthalates underscore the importance of continued monitoring and regulation to mitigate their risks(**Wittassek et al.,2008**).

Phthalates represent a diverse group of chemical compounds extensively used as plasticizers in various industrial applications. These compounds are characterized by their ability to improve the flexibility, durability, and transparency of plastics, making them essential components in products ranging from PVC plastics to personal care items(**Lyche et al.,2017**). Among the numerous types of phthalates, some of the most commonly encountered include diethyl phthalate (DEP), dimethyl phthalate (DMP), dibutyl phthalate (DBP), di(2-ethylhexyl) phthalate (DEHP), and benzyl butyl phthalate (BBP)(**Mankidy et al.,2013**).



Fig 1: It shows the classification of heavy molecular weight Phthalates (Ishido et al.,2014)

Diethyl phthalate (DEP) is often employed in personal care products such as fragrances, lotions, and cosmetics due to its ability to enhance the scent and texture of these items(**Ishido et al.,2014**). Dimethyl phthalate (DMP) is utilized as a plasticizer in cellulose-based plastics and as a solvent in pesticides and other industrial applications(**Xu et al.,2009**). Dibutyl phthalate (DBP) is commonly found in nail polish, adhesives, and sealants, contributing to their flexibility and adhesion properties(**Aylward et al.,2009**). Di(2-ethylhexyl) phthalate (DEHP) is one of the most widely used phthalates, employed primarily in PVC products such as flooring, cables, and medical devices. Finally, benzyl butyl phthalate (BBP) is utilized in various consumer goods, including vinyl flooring, automotive parts, and adhesives, to improve their flexibility and resilience(**Planelló et al.,2011**).

Studying the effects of phthalates on human health is of paramount importance due to their widespread use and potential risks to individuals(**Fabjan et al.,2006**). Phthalates are ubiquitous in our

environment, found in numerous consumer products such as plastics, cosmetics, and personal care items(**Koch et al.,2009**). Research has suggested that exposure to certain types of phthalates may be linked to adverse health outcomes, including disruptions in endocrine function, reproductive issues, developmental abnormalities, and respiratory problems(**Wang et al.,2021**). Understanding the mechanisms through which phthalates impact human health is crucial for informing public health policies and regulations aimed at minimizing exposure and mitigating potential risks(**Schettler et al.,2006**). Moreover, identifying vulnerable populations, such as pregnant women, infants, and children, who may be more susceptible to the effects of phthalate exposure, is essential for implementing targeted interventions and protective measures (**Julinová et al.,2012**). By studying the effects of phthalates on human health comprehensively, researchers can contribute to the development of safer alternatives and promote healthier environments for all individuals(**Li et al.,2011).**

Objective of my Review:-

The objectives of my study are to comprehensively review the current literature on phthalates, focusing on their sources, exposure pathways, health effects, and regulatory measures. By synthesizing existing research findings, the review aims to provide a thorough understanding of the potential risks posed by phthalates to human health and the environment. Additionally, the study seeks to identify gaps in knowledge and areas requiring further investigation, thereby contributing to the development of evidence-based policies and interventions aimed at reducing phthalate exposure and safeguarding public health.

2. Factors InfluencingSources and Exposure Routes

Phthalates can leach into the environment from landfills and waste disposal sites, contaminating soil, water, and air. They can also enter the food chain through packaging materials, food processing equipment, and agricultural practices, further amplifying exposure pathways. Indoor air pollution from phthalate-containing products, as well as dust accumulation in indoor environments, represents additional sources of exposure, particularly in homes and workplaces **(Koch et al.,2009).**

Firstly, the source of exposure plays a significant role, with phthalates leaching from plastics, cosmetics, and other products into the environment (**Koniecki et al.,2011**). Environmental conditions such as temperature and humidity can exacerbate this process, increasing the release of phthalates into the air and food(**Birnbaum et al.,2013**). Lifestyle choices, including diet and personal care habits, also affect exposure levels, with processed foods and frequent use of phthalate-containing products contributing to higher exposures(**Serrano et al.,2014**). Additionally, demographic factors like age and socioeconomic status can influence exposure, with children and individuals from disadvantaged backgrounds often facing elevated levels due to behavioral patterns and living conditions(**Giuliani et al.,2020**). Regulatory measures, such as restrictions on phthalate use in certain products and labeling requirements, also impact exposure levels by guiding consumer choices and minimizing occupational exposure risks. Overall, a combination of sources, environmental conditions, lifestyle factors, demographics, and regulatory actions collectively determine the extent of human exposure to phthalates, underscoring the importance of comprehensive approaches to mitigate potential health risks associated with these chemicals (**Duty et al.,2003).**

3. Metabolism and Bioaccumulation

3.1. Metabolic Pathways of Phthalates in the Human Body

Upon exposure, phthalates undergo biotransformation primarily in the liver through phase I and phase II metabolism pathways (**Frederiksen et al.,2007**). Phase I metabolism involves enzymatic reactions, including oxidation, reduction, and hydrolysis, which convert phthalates into various metabolites. For example, diethyl phthalate (DEP) can be metabolized to monoethyl phthalate (MEP) through hydrolysis, while di(2-ethylhexyl) phthalate (DEHP) undergoes oxidation to form its primary metabolite, mono(2-ethylhexyl) phthalate (MEHP) (**Zhang et al.,2021**).Phase II metabolism involves conjugation reactions, where the metabolites produced in phase I are further modified to enhance their solubility and facilitate excretion (**Benjamin et al.,2017).** Conjugation with glucuronic acid is a major pathway for phthalate metabolism, yielding glucuronidated metabolites such as mono(2-ethylhexyl) phthalate-glucuronide (MEHP-Gluc). Other phase II conjugation reactions include sulfation and glutathione conjugation, leading to the formation of sulfate and mercapturic acid conjugates, respectively**(Medic et al.,2015).**

The metabolism of phthalates can also involve bioactivation pathways, where reactive metabolites are formed that may exert toxic effects. For instance, DEHP can be metabolized to its monoester form, MEHP, which has been shown to induce oxidative stress, disrupt endocrine function, and impair reproductive health in experimental studies (**Jeong et al.,2020**).DiNP undergoes biotransformation primarily in the liver through phase I and phase II metabolism pathways**(Katsikantami et al., 2016)**. Phase I metabolism involves enzymatic reactions, including oxidation, reduction, and hydrolysis, which convert DiNP into various metabolites (**Weiss et al.,2018**). For example, DiNP can be hydrolyzed to form monoisononyl phthalate (MiNP) and subsequently oxidized to form its primary oxidative metabolite, mono(isononyl) phthalate mono(2-ethylhexyl) ester (MINP-MEHE)**(Silva et al.,2006**).

Phase II metabolism involves conjugation reactions, where the metabolites produced in phase I are further modified to enhance their solubility and facilitate excretion. Conjugation with glucuronic acid is a major pathway for DiNP metabolism, yielding glucuronidated metabolites such as mono(isononyl) phthalate glucuronide (MiNP-Gluc) (**Saravanabhavan et al.,2012**). Other phase II conjugation reactions include sulfation and glutathione conjugation, leading to the formation of sulfate and mercapturic acid conjugates, respectively**(Silva et al.,2006).**

3.2. Bioaccumulation in Different Tissues and Organs

The distribution of contaminants in tissues and organs is influenced by several factors, including the route of exposure, the lipid content of tissues, and the affinity of chemicals for specific organs. Lipophilic compounds tend to accumulate in fatty tissues due to their highlipid content, while water-soluble compounds may preferentially accumulate in organs with high blood flow and metabolic activity (**Gobas et al.,2003**).

3.2.1. Liver:

The liver plays a central role in the metabolism and detoxification of xenobiotics, making it a common target for bioaccumulation of environmental contaminants. Lipophilic compounds such as polychlorinated biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs), and organochlorine

pesticides tend to accumulate in the liver due to its high lipid content and metabolic activity. These chemicals can interfere with liver function, leading to hepatotoxicity, oxidative stress, and disruption of metabolic pathways**(Bhattacharya et al.,2005).**

3.2.2. Adipose Tissue:

Adipose tissue serves as a major reservoir for lipophilic chemicals, owing to its high lipid content and slow turnover rate. Persistent organic pollutants (POPs) such as dioxins, furans, and brominated flame retardants tend to accumulate in adipose tissue, where they can remain stored for extended periods. Bioaccumulation of POPs in adipose tissue has been linked to adverse health effects, including endocrine disruption, reproductive toxicity, and carcinogenicity**(Gustafson et al.,2007).**



Fig:- The Regulations shows in Adipose tissue for heath by estogen affected by Phthalates

3.2.3. Brain:

The blood-brain barrier (BBB) restricts the passage of hydrophilic molecules into the brain, limiting the bioaccumulation of water-soluble contaminants. However, lipophilic compounds with high lipid solubility can penetrate the BBB and accumulate in the brain, potentially causing neurotoxic effects. Mercury, lead, and certain pesticides are known to bioaccumulate in the brain, where they can induce neurodevelopmental abnormalities, cognitive impairment, and neurodegenerative diseases.



Fig:- it shows Traumatic brain Injury as Frequent cause oh Hypopituitarism and Growth Hormone by Phthalate (Gasco et al.,2021)

3.2.4. Kidneys:

The kidneys play a crucial role in the excretion of water-soluble metabolites and xenobiotics, making them susceptible to bioaccumulation of certain chemicals. Heavy metals such as cadmium, lead, and mercury tend to accumulate in the kidneys due to their affinity for renal tissues and prolonged half-lives. Chronic exposure to these metals can lead to renal toxicity, nephrotoxicity, and impaired renal function (**Gu et al., 2021).**

3.2.5. Bone:

Bone serves as a long-term reservoir for certain metals, particularly lead and cadmium, which have high affinities for calcium-rich tissues. These metals can accumulate in bone over time, where they may remain stored for years or even decades. Chronic exposure to lead and cadmium can lead to skeletal toxicity, bone demineralization, and increased fracture risk (**Van et al.,2020).**

3.2.6 Muscle:

Muscle tissue generally contains lower concentrations of environmental contaminants compared to adipose tissue, due to its lower lipid content and metabolic activity. However, certain lipophilic compounds may still accumulate in muscle tissue, particularly in species with high trophic levels. Persistent bioaccumulation of contaminants in muscle tissue can pose risks to human health through consumption of contaminated seafood or game animals**(Lee et al.,2020).**

4. Toxicological Effects:-

4.1 Endocrine Disrupter:-

Endocrine disruption caused by phthalates poses significant risks to human health, with potential implications for various physiological systems and developmental stages. Phthalates, a group of synthetic chemicals widely used as plasticizers in consumer products, have been implicated in

disrupting endocrine function by interfering with hormone signaling pathways. Understanding the mechanisms and health effects of endocrine disruption by phthalates is essential for assessing their risks and implementing appropriate regulatory measures to protect public health **(Habert, et al.,2009)**

Phthalates can disrupt endocrine function through multiple mechanisms, including hormone mimicry, hormone modulation, and interference with hormone synthesis or metabolism. These mechanisms can lead to dysregulation of hormonal balance and perturbations in physiological processes critical for human health **(Huang et al.,2012).**

Phthalates, such as di(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate (DBP), exhibit structural similarities to natural hormones, allowing them to bind to hormone receptors and activate or inhibit hormonal signaling pathways. For example, DEHP has been shown to mimic the actions of estrogen, leading to estrogenic effects in various tissues and organs **(Chen at al.,2014)**

Phthalates can interfere with hormone synthesis, metabolism, or transport, leading to alterations in hormone levels and biological responses. For instance, DEHP has been found to inhibit testosterone synthesis and disrupt steroidogenesis in the testes, leading to reproductive .



Fig2:- the adverse impacts of phthalates on human health, analyze the toxicity mechanism, assess the risks, and finally provide feasible strategies to reduce exposure of the public to phthalates (Martino et al.,2010).

4.2 Reproductive Toxicity:-

Epidemiological studies have provided valuable insights into the reproductive toxicity of phthalates in humans. These studies have shown associations between phthalate exposure and various reproductive outcomes, including reduced fertility, impaired sperm quality, altered hormone levels, and adverse pregnancy outcomes. For example, research has linked higher urinary levels of phthalate metabolites to decreased sperm concentration, motility, and morphology in men, as well as increased risk of pregnancy loss and preterm birth in women. Additionally, prenatal exposure to phthalates has been associated with adverse reproductive outcomes in offspring, such as genital abnormalities, impaired reproductive development, and altered reproductive hormone levels (**Martino et al.,2010**).Animal studies have been instrumental in elucidating the mechanisms and reproductive toxicity of phthalates. These experiments typically involve controlled exposure to phthalates in laboratory animals, followed by assessment of reproductive parameters, hormone levels, and histological changes in reproductive tissues (**Sedha et al.,2021**). Animal models, including rodents, fish, and amphibians, have demonstrated reproductive toxicity effects of phthalates similar to those observed in humans**(Czubacka et al 2021**). For instance, rodent studies have shown that exposure to phthalates during critical periods of reproductive development can lead to testicular toxicity, ovarian dysfunction, disrupted estrouscyclicity, and reduced fertility. These effects may result from phthalate-induced alterations in hormone synthesis, receptor binding, steroidogenesis, and gonadal development (**Svechnikov et al.,2016).**

Mechanisms of Reproductive Toxicity:

Phthalates can disrupt reproductive function through various mechanisms, including hormone mimicry, hormone modulation, and interference with steroidogenesis. These mechanisms can lead to hormonal imbalances, impaired gametogenesis, altered reproductive organ development, and compromised fertility. For example, some phthalates, such as di(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate (DBP), exhibit anti-androgenic activity, antagonizing the actions of testosterone and dihydrotestosterone (DHT) in the male reproductive system. Other phthalates, such as butyl benzyl phthalate (BBP) and diethyl phthalate (DEP), have estrogenic properties and can mimic the actions of natural estrogens, disrupting hormone signaling pathways in the female reproductive system. Additionally, phthalates may interfere with gonadotropin signaling, inhibit steroid hormone synthesis enzymes, and disrupt germ cell development in the testes and ovaries**(Lovekamp et al., 2003).**

4.3. Developmental effects:-

Understanding the developmental effects of phthalates in both humans and animal models is critical for assessing the potential health risks associated with exposure and implementing appropriate regulatory measures to protect vulnerable populations (**Kay et al.,2013**).

Epidemiological studies have provided valuable insights into the developmental effects of phthalates in humans. These studies have shown associations between prenatal or early-life exposure to phthalates and various developmental outcomes, including birth defects, neurodevelopmental disorders,

behavioral abnormalities, and altered growth patterns. For example, research has linked higher maternal urinary levels of phthalate metabolites during pregnancy to increased risk of genital abnormalities, such as hypospadias and cryptorchidism, in male offspring (**Habert et al.,2009**). Additionally, prenatal exposure to phthalates has been associated with neurodevelopmental impairments, such as decreased IQ, attention deficit hyperactivity disorder (ADHD), and autism spectrum disorder (ASD), in children**(North et al.,2014).**

Animal studies have been instrumental in elucidating the mechanisms and developmental effects of phthalates. These experiments typically involve controlled exposure to phthalates in laboratory animals, followed by assessment of developmental parameters, neurobehavioral outcomes, and histological changes in target tissues. Animal models, including rodents, fish, and amphibians, have demonstrated developmental effects of phthalates similar to those observed in humans**(Mariana et al.,2016**). For instance, rodent studies have shown that prenatal exposure to phthalates can lead to fetal growth restriction, skeletal malformations, altered brain structure and function, and behavioral abnormalities in offspring. These effects may result from phthalate-induced disruptions in hormone-sensitive pathways involved in organogenesis, neurodevelopment, and cellular differentiation **(Pu et al.,2020)**

Phthalates can disrupt normal development through various mechanisms, including hormone modulation, interference with gene expression, oxidative stress, and epigenetic alterations. These mechanisms can perturb critical processes such as cell proliferation, differentiation, migration, and apoptosis, leading to structural and functional abnormalities in developing tissues and organs. For example, some phthalates, such as di(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate (DBP), exhibit anti-androgenic activity, antagonizing the actions of testosterone and dihydrotestosterone (DHT) during fetal masculinization, leading to genital abnormalities in male offspring. Other phthalates, such as butyl benzyl phthalate (BBP) and diethyl phthalate (DEP), have estrogenic properties and can disrupt hormone signaling pathways involved in brain development and sexual differentiation in both male and female foetuses**(Mesquita,et al.,2021**).

4.4. Carcinogenicity Effects:-

Epidemiological studies have provided valuable insights into the carcinogenic effects of phthalates in humans. These studies have shown associations between phthalate exposure and increased risk of hormone-related cancers, including breast, prostate, ovarian, and testicular cancers. For example, research has linked higher urinary levels of phthalate metabolites to elevated breast cancer risk in women, as well as increased prostate cancer incidence in men. Additionally, occupational exposure to phthalates has been associated with higher rates of liver cancer, lung cancer, and hematopoietic malignancies in exposed workers. These findings suggest a potential link between phthalate exposure and cancer risk in humans, particularly for hormonally sensitive tumors **(Kluwe et al.,1982).**

Animal studies have been instrumental in elucidating the mechanisms and carcinogenic effects of phthalates. These experiments typically involve controlled exposure to phthalates in laboratory animals, followed by assessment of tumor incidence, tumor multiplicity, histological changes, and molecular alterations in target tissues (**Wang et al.,2012**). Animal models, including rodents, fish, and birds, have demonstrated carcinogenic effects of phthalates similar to those observed in humans (**Wang et al.,2012**). For instance, rodent studies have shown that chronic exposure to certain phthalates, such as di(2-ethylhexyl) phthalate (DEHP) and diisononyl phthalate (DINP), can increase the incidence of liver tumors, testicular tumors, and mammary tumors in exposed animals**(Mckee et al.,2000**). These

carcinogenic effects may result from phthalate-induced disruptions in hormone signaling pathways, oxidative stress, DNA damage, and epigenetic alterations in target tissues.

4.5. Immunotoxicity:-

Animal studies have been instrumental in elucidating the mechanisms and immunotoxic effects of phthalates. These experiments typically involve controlled exposure to phthalates in laboratory animals, followed by assessment of immune parameters, cytokine profiles, antibody responses, and histological changes in immune organs. Animal models, including rodents, fish, and birds, have demonstrated immunotoxic effects of phthalates similar to those observed in humans(**Burgos et al.,2021**). For instance, rodent studies have shown that exposure to certain phthalates, such as di(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate (DBP), can suppress immune cell proliferation, alter cytokine secretion profiles, and impair immune responses to infectious agents. These immunotoxic effects may result from phthalate-induced alterations in immune cell function, inflammatory signaling pathways, and oxidative stress in target tissues (**Zhang et al.,2022**).

Mechanisms of Immunotoxicity:

Phthalates can disrupt immune function through various mechanisms, including modulation of immune cell activity, dysregulation of cytokine production, alteration of antigen-presenting cell function, and induction of oxidative stress (**Xu et al.,2012**). These mechanisms can impair immune surveillance, compromise host defense mechanisms, and increase susceptibility to infections, allergic reactions, autoimmune disorders, and inflammatory diseases. For example, some phthalates, such as DEHP and BBP, can inhibit T-cell proliferation, suppress natural killer (NK) cell activity, and disrupt cytokine balance, leading to immunosuppression and impaired immune responses (**Xu et al.,2013**). Other phthalates, such as DEHP and DBP, can induce oxidative stress and inflammation in immune organs, such as the thymus and spleen, leading to tissue damage and dysfunction**(Steensen et al.,2016).**

4.6. Neurotoxicity:-

Epidemiological studies have provided valuable insights into the neurotoxic effects of phthalates in humans. These studies have shown associations between prenatal or early-life exposure to phthalates and various neurodevelopmental outcomes, including cognitive deficits, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and behavioral problems (**Fucic et al.,2021**). For example, research has linked higher urinary levels of phthalate metabolites during pregnancy to decreased IQ scores, impaired executive function, and increased risk of neurodevelopmental disorders in children. Additionally, childhood exposure to phthalates has been associated with hyperactivity, aggression, and social withdrawal in school-aged children (**Mallozzi et al.,2016**).

Animal studies have been instrumental in elucidating the mechanisms and neurotoxic effects of phthalates. These experiments typically involve controlled exposure to phthalates in laboratory animals, followed by assessment of neurobehavioral outcomes, neuronal morphology, neurotransmitter levels, and synaptic plasticity in the brain**(Holahan et al.,2016).** Animal models, including rodents, fish, and non-human primates, have demonstrated neurotoxic effects of phthalates similar to those observed in humans. For instance, rodent studies have shown that prenatal exposure to certain phthalates, such as di(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate (DBP), can lead to alterations in brain

structure, impaired neuronal migration, synaptic dysfunction, and behavioral abnormalities in offspring. These neurotoxic effects may result from phthalate-induced disruptions in neurogenesis, neuronal differentiation, axonal growth, and synaptic connectivity in the developing brain (**Hlisníková et ai.,2021**).

Mechanisms of Neurotoxicity:

Phthalates can induce neurotoxicity through various mechanisms, including disruption of neurotransmitter systems, interference with neuronal signaling pathways, oxidative stress, inflammation, and mitochondrial dysfunction. These mechanisms can lead to neuronal damage, synaptic dysfunction, neuroinflammation, and impaired neuronal plasticity, contributing to cognitive deficits and behavioral abnormalities(**Tran et al.,2021**). For example, some phthalates, such as DEHP and BBP, can interfere with dopamine and serotonin signaling pathways in the brain, leading to alterations in mood, cognition, and behavior. Other phthalates, such as DEHP and DBP, can induce oxidative stress and inflammation in the brain, leading to neuronal apoptosis, glial activation, and white matter damage. Additionally, phthalates may disrupt mitochondrial function and energy metabolism in neurons, further exacerbating neurotoxicity and neuronal dysfunction (**Liu et al.,2023**).

5. Epidermiological Evidence:-

Epidemiological evidence linking phthalate exposure to various health outcomes has emerged as a critical component of public health research in recent years. Phthalates, a class of chemical compounds commonly used as plasticizers in numerous consumer products, have raised concerns due to their potential adverse effects on human health. Epidemiological studies investigating the associations between phthalate exposure and health outcomes in human populations have provided valuable insights into the potential risks posed by these ubiquitous environmental contaminants (**Benjamin et al.,2017**).

Phthalates are known to be present in a wide range of consumer products, including plastics, personal care products, food packaging, and medical devices. Consequently, human exposure to phthalates is widespread, occurring through ingestion, inhalation, and dermal contact with contaminated products. Biomonitoring studies have detected phthalate metabolites in urine, blood, breast milk, and other biological samples, indicating pervasive exposure among individuals of all ages and demographic groups(**Radke et al.,2019**).

One area of concern regarding phthalate exposure is its potential impact on reproductive health. Epidemiological studies have reported associations between phthalate exposure and adverse reproductive outcomes, including reduced fertility, impaired sperm quality, menstrual irregularities, and pregnancy complications. For example, research has linked higher urinary levels of phthalate metabolites to decreased sperm concentration, motility, and morphology in men, as well as increased risk of miscarriage and preterm birth in women. Additionally, prenatal exposure to phthalates has been associated with altered genital development, reduced anogenital distance, and endocrine disruption in male offspring, highlighting the potential developmental effects of phthalates on reproductive function (**Radke et al.,2018**).

In addition to reproductive health, epidemiological evidence suggests that phthalate exposure may impact other physiological systems, including the endocrine, immune, respiratory, and nervous systems. Phthalates have been implicated in disrupting hormone signaling pathways, modulating immune responses, exacerbating respiratory conditions, and affecting neurodevelopment and cognitive function. For instance, research has linked phthalate exposure to increased risk of hormone-related cancers, such as breast, prostate, and ovarian cancers, as well as respiratory conditions, such as asthma and allergies. Furthermore, prenatal exposure to phthalates has been associated with neurodevelopmental disorders, including attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and cognitive deficits in children (**Jeddi et al.,2016**).

The mechanisms underlying the health effects of phthalates are complex and multifaceted. Phthalates can act as endocrine-disrupting chemicals, interfering with hormone synthesis, metabolism, and receptor signaling. They can also induce oxidative stress, inflammation, and mitochondrial dysfunction, leading to cellular damage and dysfunction in various organs and tissues. Moreover, phthalates may exert epigenetic effects, altering gene expression patterns and contributing to long-term health effects across multiple generations**(Qifan et al.,2021).**

Despite the growing body of epidemiological evidence linking phthalate exposure to adverse health outcomes, several challenges and limitations remain. Epidemiological studies are inherently observational in nature, making it difficult to establish causality or infer direct cause-effect relationships between phthalate exposure and health outcomes. Additionally, exposure assessment in epidemiological studies may be subject to measurement errors, resulting in exposure misclassification and attenuated associations. Furthermore, confounding by other environmental contaminants, lifestyle factors, and sociodemographic variables can confound the observed associations, complicating interpretation and generalization of study findings(**Kim et al.,2021**).

6. Mechanisms of Action

Phthalates have been shown to interact with hormone receptors through various mechanisms, including:

i. Estrogen Receptors (ERs):

Phthalates, such as diethyl phthalate (DEP) and butyl benzyl phthalate (BBP), can bind to estrogen receptors, including ERα and ERβ, and activate estrogenic signaling pathways. This can lead to estrogenic effects, such as cell proliferation, gene expression changes, and hormone-dependent growth of estrogen-sensitive tissues. However, some phthalates, like di(2-ethylhexyl) phthalate (DEHP), exhibit both estrogenic and anti-estrogenic properties, depending on the dose and context of exposure (**Hannon et al.,2015**).

ii. Androgen Receptors (ARs):

Certain phthalates, such as DEHP and dibutyl phthalate (DBP), have been shown to interfere with androgen receptor signaling by acting as anti-androgens. These phthalates can compete with endogenous androgens for binding to the androgen receptor, thereby blocking androgen-mediated

transcriptional activity and disrupting androgen-dependent developmental processes, such as masculinization of the reproductive tract(**Beg et al.,2020).**

iii.Thyroid Hormone Receptors (THR):

Phthalates, particularly DEHP and its metabolites, have been implicated in thyroid hormone disruption by interfering with thyroid hormone receptor (THR) signaling. Phthalates can alter thyroid hormone levels, inhibit thyroid hormone synthesis, and disrupt thyroid hormone-dependent processes, such as metabolism, growth, and development. This can lead to adverse health effects, including developmental abnormalities, metabolic dysfunction, and neurobehavioral impairments (**Sarath et al.,2014).**

iv. Transcriptional Regulation:

Phthalates can affect gene expression by modulating the activity of transcription factors, which regulate the initiation and regulation of gene transcription. Phthalates may influence the expression of genes involved in inflammation, oxidative stress, apoptosis, and cell cycle regulation, thereby affecting cellular processes and contributing to adverse health outcomes(**Nazzari et al.,2023**).

V.Epigenetic Modifications:

Phthalates have been implicated in epigenetic alterations, such as changes in DNA methylation patterns, histone modifications, and microRNA expression profiles. These epigenetic changes can influence gene expression patterns and cellular function, leading to long-term effects on health and disease risk (**Xu et al.,2020**).

Vi.Oxidative Stress and Inflammation:

Phthalates can induce oxidative stress and inflammation in cells and tissues, leading to alterations in gene expression profiles associated with antioxidant defense, immune response, and inflammatory signaling pathways. These gene expression changes may contribute to the development of oxidative damage, inflammatory diseases, and other adverse health effects(**van et ai.,2019**).Phthalates have been shown to disrupt mitochondrial function, leading to alterations in energy metabolism, oxidative phosphorylation, and reactive oxygen species (ROS) production. These mitochondrial effects can influence gene expression patterns involved in cellular metabolism, apoptosis, and oxidative stress response, contributing to cellular dysfunction and tissue damage (**Ashari et al.,2020**).

7.Regulatory Status and Exposure Limits

The regulatory status and exposure limits for phthalates vary across different countries and regulatory agencies. While phthalates have been widely used in consumer products for decades, concerns about their potential adverse health effects have prompted regulatory actions aimed at reducing human exposure and protecting public health. Here, we discuss the regulatory status and exposure limits for phthalates in several key regions (**Estill et al.,2019**).

In the United States, the regulation of phthalates falls under various federal agencies, including the Environmental Protection Agency (EPA), Food and Drug Administration (FDA), and Consumer Product Safety Commission (CPSC). The EPA regulates phthalates as part of the Toxic Substances Control Act (TSCA), which grants the agency authority to assess and regulate chemical substances for their potential risks to human health and the environment (**Birnbaum et al.,2013).**

The FDA regulates the use of phthalates in food contact materials, cosmetics, and other consumer products under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The agency has established specific regulations and guidelines for phthalate levels in food packaging materials and cosmetic products to ensure safety for consumers (**Wallack et al.,2019).**

Additionally, the CPSC regulates the use of phthalates in children's products, such as toys and childcare articles, under the Consumer Product Safety Improvement Act (CPSIA). The CPSC has banned the use of certain phthalates, including di(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), and benzyl butyl phthalate (BBP), in children's products due to their potential health risks (**Ellis et al.,2019**)

i. European Union:

In the European Union (EU), phthalates are regulated under the Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) Regulation, which aims to ensure the safe use of chemicals and protect human health and the environment. Phthalates are subject to strict regulations and restrictions under REACH, including authorization requirements for certain high-risk substances (**Nakiwala et al.,2020**).The EU has also established specific regulations and directives governing the use of phthalates in consumer products, such as the Restriction of Hazardous Substances (RoHS) Directive and the Directive on the Safety of Toys. These directives restrict the use of certain phthalates, including DEHP, DBP, and BBP, in electronic devices, toys, and childcare articles intended for sale in the EU market**(Monti et al.,2022).**

ii. International Standards:

Several international organizations, such as the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), have evaluated the health risks associated with phthalate exposure and provided recommendations for exposure limits and risk management strategies.The WHO has established guidelines for acceptable levels of phthalates in drinking water and ambient air to protect public health. Additionally, the IARC has classified certain phthalates, such as DEHP, as possible human carcinogens based on evidence of carcinogenicity in animal studies (**Huang et al.,2009**).

8. Risk Assessment and Management

Risk assessment and management of phthalates involve evaluating the potential health risks associated with exposure to these chemicals and implementing strategies to minimize or mitigate those risks. The process of risk assessment typically involves four key steps: hazard identification, exposure assessment, dose-response assessment, and risk characterization. Hazard identification involves identifying the adverse health effects associated with phthalate exposure, such as reproductive toxicity, developmental effects, carcinogenicity, and endocrine disruption. Exposure assessment quantifies the levels of phthalate exposure in human populations through biomonitoring, environmental monitoring, and exposure modeling. Dose-response assessment evaluates the relationship between phthalate exposure levels and the likelihood or severity of adverse health effects based on available toxicological data. Risk characterization integrates hazard identification, exposure assessment, and dose-response assessment to estimate the magnitude of the health risks posed by phthalate exposure and informs risk management decisions**(National Research Council 2009).**

Risk management strategies aim to minimize or mitigate the identified health risks associated with phthalate exposure through regulatory measures, public health interventions, and industry practices. Regulatory agencies may establish exposure limits, guidelines, and standards for phthalate levels in consumer products, food packaging, and environmental media based on risk assessment findings. These regulations may include bans or restrictions on the use of certain phthalates in specific applications, such as children's products or food contact materials. Public health interventions may focus on education, outreach, and awareness campaigns to inform the public about the potential risks of phthalate exposure and promote safer alternatives. Industry practices may involve reformulating products to reduce or eliminate phthalate content, implementing quality control measures to ensure compliance with regulatory requirements, and adopting safer manufacturing processes (**Chung et al.,2019**).

9. Conclusions and Future Directions

In conclusion, the evidence from epidemiological studies, experimental research, and regulatory actions highlights the significant health risks associated with phthalate exposure. Phthalates have been implicated in various adverse health outcomes, including reproductive toxicity, developmental effects, endocrine disruption, neurotoxicity, and immunotoxicity. While considerable progress has been made in understanding the mechanisms of action and health effects of phthalates, several challenges and knowledge gaps remain.

Future research directions should focus on elucidating the molecular mechanisms underlying the health effects of phthalates, exploring the interactions between phthalates and other environmental contaminants, assessing the cumulative effects of phthalate mixtures, and identifying susceptible populations, such as pregnant women, infants, and children. Additionally, efforts should be directed towards developing sensitive biomarkers of exposure and effect, improving exposure assessment methods, and evaluating the long-term health effects of low-dose phthalate exposure.

From a regulatory standpoint, continued monitoring of phthalate levels in consumer products, food packaging, and environmental media is essential to ensure compliance with existing regulations and inform risk management decisions. Regulatory agencies should consider updating exposure limits and guidelines based on emerging scientific evidence and implementing measures to promote the use of safer alternatives to phthalates in consumer products and industrial applications.

In summary, addressing the health risks associated with phthalate exposure requires a multidisciplinary approach involving collaboration between researchers, policymakers, industry stakeholders, and the public. By advancing our understanding of the health effects of phthalates and implementing effective risk management strategies, we can minimize exposure, protect human health, and create a safer environment for current and future generations.

Reference:

1. Hauser, R., &Calafat, A. M. (2005). Phthalates and human health. *Occupational and environmental medicine*, *62*(11), 806-818.
2. Wittassek, M., &Angerer, J. (2008). Phthalates: metabolism and exposure. *International journal of andrology*, *31*(2), 131-138.
3. Lyche, J. L. (2017). Phthalates. In *Reproductive and developmental toxicology* (pp. 829-856). Academic Press.
4. Mankidy, R., Wiseman, S., Ma, H., &Giesy, J. P. (2013). Biological impact of phthalates. *Toxicology letters*, *217*(1), 50-58.
5. Ishido, M., & Suzuki, J. (2014). Classification of phthalates based on an in vitro neurosphere assay using rat mesencephalic neural stem cells. *The Journal of Toxicological Sciences*, *39*(1), 25-32.
6. Xu, B., Gao, N. Y., Cheng, H., Xia, S. J., Rui, M., & Zhao, D. D. (2009). Oxidative degradation of dimethyl phthalate (DMP) by UV/H2O2 process. *Journal of Hazardous Materials*, *162*(2-3), 954-959.
7. Aylward, L. L., Hays, S. M., Gagné, M., & Krishnan, K. (2009). Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP). *Regulatory Toxicology and Pharmacology*, *55*(3), 259-267.
8. Koch, H. M., Preuss, R., &Angerer, J. D. (2006). Di (2-ethylhexyl) phthalate (DEHP): human metabolism and internal exposure–an update and latest results 1. *International journal of andrology*, *29*(1), 155-165.
9. Planelló, R., Herrero, O., Martínez-Guitarte, J. L., &Morcillo, G. (2011). Comparative effects of butyl benzyl phthalate (BBP) and di (2-ethylhexyl) phthalate (DEHP) on the aquatic larvae of Chironomusriparius based on gene expression assays related to the endocrine system, the stress response and ribosomes. *Aquatic toxicology*, *105*(1-2), 62-70.
10. Fabjan, E., Hulzebos, E., Mennes, W., &Piersma, A. H. (2006). A category approach for reproductive effects of phthalates. *Critical reviews in toxicology*, *36*(9), 695-726.
11. Katsikantami, I., Sifakis, S., Tzatzarakis, M. N., Vakonaki, E., Kalantzi, O. I., Tsatsakis, A. M., &Rizos, A. K. (2016). A global assessment of phthalates burden and related links to health effects. *Environment international*, *97*, 212-236.
12. Koch, H. M., &Calafat, A. M. (2009). Human body burdens of chemicals used in plastic manufacture. *Philosophical Transactions of the Royal Society B: Biological Sciences*, *364*(1526), 2063-2078.
13. Wang, Y., &Qian, H. (2021, May). Phthalates and their impacts on human health. In *Healthcare* (Vol. 9, No. 5, p. 603). MDPI.
14. Schettler, T. (2006). Human exposure to phthalates via consumer products. International Journal of Andrology, 29(1), 134–139.
15. Julinová, M., &Slavík, R. (2012). Removal of phthalates from aqueous solution by different adsorbents: a short review. *Journal of environmental management*, *94*(1), 13-24.
16. Li, Z., Xu, L., Peng, C., Kuang, H., Xu, C., Wang, L., ...& Gong, Y. (2011). Simultaneous determination of nine types of phthalate residues in commercial milk products using HPLC-ESI-MS-MS. *Journal of chromatographic science*, *49*(4), 337-343.
17. Koniecki, D., Wang, R., Moody, R. P., & Zhu, J. (2011). Phthalates in cosmetic and personal care products: concentrations and possible dermal exposure. *Environmental research*, *111*(3), 329-336.
18. Birnbaum, L. S., &Schug, T. T. (2013). Phthalates in our food. *Endocrine disruptors*, *1*(1), e25078.

19. Serrano, S. E., Braun, J., Trasande, L., Dills, R., &Sathyanarayana, S. (2014). Phthalates and diet: a review of the food monitoring and epidemiology data. *Environmental Health*, *13*, 1-14.
20. Giuliani, A., Zuccarini, M., Cichelli, A., Khan, H., &Reale, M. (2020). Critical review on the presence of phthalates in food and evidence of their biological impact. *International journal of environmental research and public health*, *17*(16), 5655.
21. Duty, S. M., Silva, M. J., Barr, D. B., Brock, J. W., Ryan, L., Chen, Z., Herrick, R. F., Christiani, D. C., & Hauser, R. (2003). Phthalate exposure and human semen parameters. Epidemiology, 14(3), 269–277.
22. Frederiksen, H., Skakkebaek, N. E., &Andersson, A. M. (2007). Metabolism of phthalates in humans. *Molecular nutrition & food research*, *51*(7), 899-911.
23. Zhang, Y. J., Guo, J. L., Xue, J. C., Bai, C. L., &Guo, Y. (2021). Phthalate metabolites: Characterization, toxicities, global distribution, and exposure assessment. *Environmental Pollution*, *291*, 118106.
24. Benjamin, S., Masai, E., Kamimura, N., Takahashi, K., Anderson, R. C., & Faisal, P. A. (2017). Phthalates impact human health: Epidemiological evidences and plausible mechanism of action. *Journal of hazardous materials*, *340*, 360-383.
25. Medic Stojanoska, M., Milankov, A., Vukovic, B., Vukcevic, D., Sudji, J., Bajkin, I., ...&Milic, N. (2015). Do diethyl phthalate (DEP) and di-2-ethylhexyl phthalate (DEHP) influence the metabolic syndrome parameters? Pilot study. *Environmental monitoring and assessment*, *187*, 1-9.
26. Jeong, S. H., Jang, J. H., Cho, H. Y., & Lee, Y. B. (2020). Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate. *Archives of Toxicology*, *94*, 2377-2400.
27. Weiss, J. M., Gustafsson, Å.,Gerde, P., Bergman, Å., Lindh, C. H., &Krais, A. M. (2018). Daily intake of phthalates, MEHP, and DINCH by ingestion andinhalation. *Chemosphere*, *208*, 40-49.
28. Silva, M. J., Reidy, J. A., PreauJr, J. L., Needham, L. L., &Calafat, A. M. (2006). Oxidative metabolites of diisononyl phthalate as biomarkers for human exposureassessment. *Environmental health perspectives*, *114*(8), 1158-1161.
29. Gu, Y., Gao, M., Zhang, W., Yan, L., Shao, F., & Zhou, J. (2021). Exposure to phthalates DEHP and DINP May lead to oxidative damage and lipidomic disruptions in mouse kidney. *Chemosphere*, *271*, 129740.
30. Katsikantami, I., Sifakis, S., Tzatzarakis, M. N., Vakonaki, E., Kalantzi, O. I., Tsatsakis, A. M., &Rizos, A. K. (2016). A global assessment of phthalates burden and related links to health effects. Environmental International, 97, 212–236.
31. Saravanabhavan, G., & Murray, J. (2012). Human biological monitoring of diisononyl phthalate and diisodecyl phthalate: a review. *Journal of Environmental and Public Health*, *2012*.
32. Silva, M. J., Kato, K., Wolf, C., Samandar, E., Silva, S. S., Gray, E. L., ...&Calafat, A. M. (2006). Urinary biomarkers of di-isononyl phthalate in rats. *Toxicology*, *223*(1-2), 101-112.
33. Gobas, F. A., Mackintosh, C. E., Webster, G., Ikonomou, M., Parkerton, T. F., &Robillard, K. (2003). Bioaccumulation of phthalate esters in aquatic food-webs. *Series Anthropogenic Compounds: Phtalate Esters*, 201-225.
34. Bhattacharya, N., Dufour, J. M., Vo, M. N., Okita, J., Okita, R., & Kim, K. H. (2005). Differential effects of phthalates on the testis and the liver. *Biology of reproduction*, *72*(3), 745-754.

35. Gustafson, B., Hammarstedt, A., Andersson, C. X., & Smith, U. (2007). Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. *Arteriosclerosis, thrombosis, and vascular biology*, *27*(11), 2276-2283.
36. Gasco, V., Cambria, V., Bioletto, F., Ghigo, E., &Grottoli, S. (2021). Traumatic brain injury as frequent cause of hypopituitarism and growth hormone deficiency: epidemiology, diagnosis, and treatment. *Frontiers in endocrinology*, *12*, 634415.(fig Brain)
37. Gu, Y., Gao, M., Zhang, W., Yan, L., Shao, F., & Zhou, J. (2021). Exposure to phthalates DEHP and DINP May lead to oxidative damage and lipidomic disruptions in mouse kidney. *Chemosphere*, *271*, 129740.
38. vanZwol-Janssens, C., Trasande, L., Asimakopoulos, A. G., Martinez-Moral, M. P., Kannan, K., Philips, E. M., ... & Santos, S. (2020). Fetal exposure to bisphenols and phthalates and childhood bone mass: a population-based prospective cohort study. *Environmental research*, *186*, 109602.
39. Lee, D. W., Lim, Y. H., Shin, C. H., Lee, Y. A., Kim, B. N., Kim, J. I., & Hong, Y. C. (2020). Prenatal exposure to di-(2-ethylhexyl) phthalate and decreased skeletal muscle mass in 6-year-old children: A prospective birth cohort study. *Environmental research*, *182*, 109020.
40. Habert, R., Muczynski, V., Lehraiki, A., Lambrot, R., LĂŠcureuil, C., Levacher, C., ...&Rouiller-Fabre, V. (2009). Adverse effects of endocrine disruptors on the foetal testis development: focus on the phthalates. *Folia HistochemicaetCytobiologica*, *47*(5), 67-74.
41. Huang, P. C., Liou, S. H., Ho, I. K., Chiang, H. C., Huang, H. I., & Wang, S. L. (2012). Phthalates exposure and endocrinal effects: an epidemiological review. *Journal of Food and Drug Analysis*, *20*(4), 23.
42. Chen, X., Xu, S., Tan, T., Lee, S. T., Cheng, S. H., Lee, F. W. F., ...&Ho, K. C. (2014). Toxicity and estrogenic endocrine disrupting activity of phthalates and their mixtures. *International journal of environmental research and public health*, *11*(3), 3156-3168.
43. Hyun Kim, D., Min Choi, S., Soo Lim, D., Roh, T., Jun Kwack, S., Yoon, S., ...& Lee, B. M. (2018). Risk assessment of endocrine disrupting phthalates and hormonal alterations in children and adolescents. *Journal of Toxicology and Environmental Health, Part A*, *81*(21), 1150-1164.
44. Martino-Andrade, A. J., &Chahoud, I. (2010). Reproductive toxicity of phthalate esters. *Molecular nutrition & food research*, *54*(1), 148-157.
45. Sedha, S., Lee, H., Singh, S., Kumar, S., Jain, S., Ahmad, A., &Bajpai, V. K. (2021). Reproductive toxic potential of phthalate compounds–State of art review. *Pharmacological Research*, *167*, 105536.
46. Czubacka, E., Czerczak, S., &Kupczewska-Dobecka, M. (2021). The overview of current evidence on the reproductive toxicity of dibutyl phthalate. *International Journal of Occupational Medicine and Environmental Health*, *34*(1).
47. Svechnikov, K., Savchuk, I., Morvan, M. L., Antignac, J. P., Le Bizec, B., &Söder, O. (2016). Phthalates exert multiple effects on leydig cell steroidogenesis. *Hormone Research in Paediatrics*, *86*(4), 253-263.
48. Lovekamp-Swan, T., & Davis, B. J. (2003). Mechanisms of phthalate ester toxicity in the female reproductive system. *Environmental health perspectives*, *111*(2), 139-145.
49. Kay, V. R., Chambers, C., & Foster, W. G. (2013). Reproductive and developmental effects of phthalate diesters in females. *Critical reviews in toxicology*, *43*(3), 200-219.
50. Habert, R., Muczynski, V., Lehraiki, A., Lambrot, R., LĂŠcureuil, C., Levacher, C., ...&Rouiller-Fabre, V. (2009). Adverse effects of endocrine disruptors on the foetal testis development: focus on the phthalates. *Folia HistochemicaetCytobiologica*, *47*(5), 67-74.

51. North, M. L., Takaro, T. K., Diamond, M. L., & Ellis, A. K. (2014). Effects of phthalates on the development and expression of allergic disease and asthma. *Annals of Allergy, Asthma & Immunology*, *112*(6), 496-502.
52. Mariana, M., Feiteiro, J., Verde, I., &Cairrao, E. (2016). The effects of phthalates in the cardiovascular and reproductive systems: A review. *Environment international*, *94*, 758-776
53. Pu, S. Y., Hamid, N., Ren, Y. W., & Pei, D. S. (2020). Effects of phthalate acid esters on zebrafish larvae: Development and skeletal morphogenesis. *Chemosphere*, *246*, 125808.
54. Mesquita, I., Lorigo, M., &Cairrao, E. (2021). Update about the disrupting-effects of phthalates on the human reproductive system. *Molecular Reproduction and Development*, *88*(10), 650-672.
55. Kluwe, W. M., McConnell, E. E., Huff, J. E., Haseman, J. K., Douglas, J. F., & Hartwell, W. V. (1982). Carcinogenicity testing of phthalate esters and related compounds by the National Toxicology Program and the National Cancer Institute. *Environmental health perspectives*, *45*, 129-133.
56. Wang, Y. C., Chen, H. S., Long, C. Y., Tsai, C. F., Hsieh, T. H., Hsu, C. Y., & Tsai, E. M. (2012). Possible mechanism of phthalates-induced tumorigenesis. *The Kaohsiung journal of medical sciences*, *28*, S22-S27.
57. Mckee, R. H., Przygoda, R. T., Chirdon, M. A., Engelhardt, G., & Stanley, M. (2000). Di (isononyl) phthalate (DINP) and di (isodecyl) phthalate (DIDP) are not mutagenic. *Journal of Applied Toxicology: An International Journal*, *20*(6), 491-497.
58. Burgos-Aceves, M. A., Abo-Al-Ela, H. G., &Faggio, C. (2021). Physiological and metabolic approach of plastic additive effects: Immune cells responses. *Journal of hazardous materials*, *404*, 124114.
59. Zhang, Y., Lyu, L., Tao, Y., Ju, H., & Chen, J. (2022). Health risks of phthalates: A review of immunotoxicity. *Environmental Pollution*, 120173.
60. Xu, H., Dong, X., Zhang, Z., Yang, M., Wu, X., Liu, H., ...& Li, C. (2015). Assessment of immunotoxicity of dibutyl phthalate using live zebrafish embryos. *Fish & Shellfish Immunology*, *45*(2), 286-292.
61. Xu, H., Shao, X., Zhang, Z., Zou, Y., Wu, X., & Yang, L. (2013). Oxidative stress and immune related gene expression following exposure to di-n-butyl phthalate and diethyl phthalate in zebrafish embryos. *Ecotoxicology and environmental safety*, *93*, 39-44.
62. Steensen, T. B. (2016). *The Effects of Di-n-Butyl Phthalate (DBP) on Human Primary Immune Cells* (Master's thesis).
63. Fucic, A., Mantovani, A., Vena, J., Bloom, M. S., Sincic, N., Vazquez, M., &Aguado-Sierra, J. (2023). Impact of endocrine disruptors from mother's diet on immuno-hormonal orchestration of brain development and introduction of the virtual human twin tool. *Reproductive Toxicology*, *117*, 108357.
64. Mallozzi, M., Bordi, G., Garo, C., & Caserta, D. (2016). The effect of maternal exposure to endocrine disrupting chemicals on fetal and neonatal development: A review on the major concerns. *Birth Defects Research Part C: Embryo Today: Reviews*, *108*(3), 224-242.
65. Holahan, M. R., & Smith, C. A. (2015). Phthalates and neurotoxic effects on hippocampal network plasticity. *Neurotoxicology*, *48*, 21-34.
66. Hlisníková, H., Petrovičová, I., Kolena, B., Šidlovská, M., &Sirotkin, A. (2021). Effects and mechanisms of phthalates' action on neurological processes and neural health: a literature review. *Pharmacological Reports*, *73*, 386-404.

67. Tran, C. M., Do, T. N., & Kim, K. T. (2021). Comparative analysis of neurotoxicity of six phthalates in zebrafish embryos. *Toxics*, *9*(1), 5.
68. Liu, Y., Guo, Z., Zhu, R., Gou, D., Jia, P. P., & Pei, D. S. (2023). An insight into sex-specific neurotoxicity and molecular mechanisms of DEHP: A critical review. *Environmental Pollution*, *316*, 120673.
69. Benjamin, S., Masai, E., Kamimura, N., Takahashi, K., Anderson, R. C., & Faisal, P. A. (2017). Phthalates impact human health: Epidemiological evidences and plausible mechanism of action. *Journal of hazardous materials*, *340*, 360-383.
70. Radke, E. G., Glenn, B. S., Braun, J. M., & Cooper, G. S. (2019). Phthalate exposure and female reproductive and developmental outcomes: a systematic review of the human epidemiological evidence. *Environment international*, *130*, 104580.
71. Radke, E. G., Braun, J. M., Meeker, J. D., & Cooper, G. S. (2018). Phthalate exposure and male reproductive outcomes: a systematic review of the human epidemiological evidence. *Environment international*, *121*, 764-793.
72. Jeddi, M. Z., Janani, L., Memari, A. H., &Akhondzadeh, S. (2016). The role of phthalate esters in autism development: A systematic review. *Environmental research*, *151*, 493-504.
73. Qifan, Y., Xuezhi, S., Hongqing, C., Qianye, C., Guofen, Z., Yufeng, L., ...&Yuemin, D. (2021). Research Progresses on the Relationship Between the Phthalates Exposure and Children's Neurodevelopmental Disorders. *Science*, *9*(3), 72-76.
74. Kim, J. I., Lee, J., Lee, K. S., Lee, Y. A., Shin, C. H., Hong, Y. C., ... & Lim, Y. H. (2021). Association of phthalate exposure with autistic traits in children. *Environment International*, *157*, 106775.
75. Hannon, P. R., & Flaws, J. A. (2015). The effects of phthalates on the ovary. *Frontiers in endocrinology*, *6*, 8.
76. Beg, M. A., & Sheikh, I. A. (2020). Endocrine disruption: structural interactions of androgen receptor against Di (2-ethylhexyl) phthalate and its metabolites. *Toxics*, *8*(4), 115.
77. Sarath Josh, M. K., Pradeep, S., VijayalekshmiAmma, K. S., Balachandran, S., Abdul Jaleel, U. C., Doble, M., ...& Benjamin, S. (2014). Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach. *Journal of applied toxicology*, *34*(7), 754-765.
78. Nazzari, M., Romitti, M., Hauser, D., Carvalho, D. J., Giselbrecht, S., Moroni, L., ...&Caiment, F. (2023). Investigation of the effects of phthalates on in vitro thyroid models with RNA-Seq and ATAC-Seq. *Frontiers in endocrinology*, *14*.
79. van' t Erve, T. J., Rosen, E. M., Barrett, E. S., Nguyen, R. H., Sathyanarayana, S., Milne, G. L., ... & Ferguson, K. K. (2019). Phthalates and phthalate alternatives have diverse associations with oxidative stress and inflammation in pregnant women. *Environmental science & technology*, *53*(6), 3258-3267.
80. Ashari, S., Karami, M., Shokrzadeh, M., Ghandadi, M., Ghassemi-Barghi, N., Dashti, A., ...&Mohammadi, H. (2020). The implication of mitochondrial dysfunction and mitochondrial oxidative damage in di (2-ethylhexyl) phthalate induced nephrotoxicity in both in vivo and in vitro models. *Toxicology mechanisms and methods*, *30*(6), 427-437.
81. Estill, M., Hauser, R., Nassan, F. L., Moss, A., &Krawetz, S. A. (2019). The effects of di-butyl phthalate exposure from medications on human sperm RNA among men. *Scientific reports*, *9*(1), 12397.
82. Birnbaum, L. S., &Schug, T. T. (2013). Phthalates in our food. *Endocrine disruptors*, *1*(1), e25078.

83. Wallack, G. (2019). Rethinking FDA'S regulation of cosmetics. *Harv. J. on Legis.*, *56*, 311.
84. , E. M., Janetos, T. M., &Xu, S. (2019). Time for a makeover-cosmetics regulation in the United States. *Journal of Cosmetic Dermatology*, *18*(6), 2041-2047.
85. Ellis, S. A. (1999). *2-Ethylhexanol: A Potential Biological Indicator of Occupational Exposure to the Plasticizer di (2-Ethylhexyl) phthalate* (Doctoral dissertation).
86. Nakiwala, D. (2020). *Prenatal exposure to phenols and phthalates, child neurodevelopment and the role of the thyroid hormones* (Doctoral dissertation, Université Grenoble Alpes [2020-....]).
87. Monti, M., Fasano, M., Palandri, L., &Righi, E. (2022). A review of European and international phthalates regulation: focus on daily use products. *European Journal of Public Health*, *32*(Supplement_3), ckac131-226.
88. Huang, P. C., Kuo, P. L., Chou, Y. Y., Lin, S. J., & Lee, C. C. (2009). Association between prenatal exposure to phthalates and the health of newborns. *Environment International*, *35*(1), 14-20.
89. National Research Council. (2009). Phthalates and cumulative risk assessment: the tasks ahead.
90. Chung, B. Y., Choi, S. M., Roh, T. H., Lim, D. S., Ahn, M. Y., Kim, Y. J., ...& Lee, B. M. (2019). Risk assessment of phthalates in pharmaceuticals. *Journal of Toxicology and Environmental Health, Part A*, *82*(5), 351-360.